Table 1

Participant baseline characteristics, overall and anti-TNF utilisation status

	Full sample (n=8502)		anti-TNF non-users (n=8186)		New episode of anti-TNF users (n=121)*
	(n)	(%)	(n)	(%)	(n)	(%)
Age mean (SD)		76 (8)		76 (8)		73 (6)
Female	6111	72	5891	72	83	69
Caucasian	7708	91	7408	91	118	98†
Region
Northeast	2104	25	2044	25	29	24
Southeast	2385	28	2278	28	40	33
Midwest	2004	24	1922	24	28	23
Rocky Mountains	239	3	234	3	<11†	–
Southwest	802	9	768	9	12	10
Pacific‡	968	11	940	12	<11†	–
Urban/suburban	6426	76	6192	76	87	72
Medicaid coverage	1915	23	1885	23	<11†	–
Polypharmacy (≥5 drugs)	4920	62	4719	62	72	60
Charlson Index Mean (SD)		1 (2)		1 (2)		1 (2)
Gastroenterologist visit	4392	52	4158	51	76	63
>1 endoscopy	1183	14	1141	14	20	17
IBD surgery	211	3	199	2	<11†	–
Hospitalisations mean (SD)		1 (1)		1 (1)		1 (1)

*New anti-TNF utilisers initiated therapy after the completion of the baseline period; bivariate analyses is the comparison of new episodes of use to non-use (n=8307); prevalent anti-TNF utilisers were already receiving therapy during the baseline study period (n=195) and were excluded from anti-TNF non-users group (n=8186).
†Cell size is too small and requires suppression as part of the data use agreement.
‡Includes Hawaii, Alaska and Puerto Rico.
IBD, inflammatory bowel disease; TNF, tumour necrosis factor.